STEPHANIE LHEUREUX MD, PhD is a Medical Oncologist, Clinician Investigator and Site Lead of Gynecology Oncology at Princess Margaret Cancer Centre. She is the Medical Director for the Rare Cancer Initiative, holds the Westaway Chair in Ovarian Cancer Research, and is an Associate Professor of Faculty of Medicine at the University of Toronto. She is also a full Member, Graduate Faculty at the Institute of Medical Science (IMS) and has supervise several fellows and PhD students. She is a member of the Investigational New Drug Program Executive Committee as part of the Canadian Cancer Trials Group (CCTG).

Her clinical and academic interests are focused in gynecologic cancers and drug development with an emphasis on translational research and have garnered two ASCO Merit awards. She received the 2019 Career Development Award from the American Society of Clinical Oncology (ASCO) and the 2021 Young Investigator Award from University of Toronto Division of Medical Oncology. In 2022, she received the Ovarian Tumor Research Network Translation Science Award.

Internationally, she is co-Chair of the Translational Research Committee and Director representing Princess Margaret Consortium at the international Gynecologic Cancer InterGroup (GCIG). She has more than 190 peer-reviewed publications in widely cited journals such as CA: Cancer Journal for Clinicians, Clinical Cancer Research, JAMA Oncology, Nature Communications, Journal of Clinical Oncology, Lancet, Lancet Oncology and Gynecology Oncology. She has been recently appointed as a Senior Editor for the Clinical Cancer Research Editorial Board from the American Association for Cancer Research (AACR).

She is principal investigator or co-principal investigator of different clinical trials and in several large-scale peer reviewed funding opportunities from the Canadian Cancer Society Research Institute, Conquer Cancer Foundation/American Society for Clinical Oncology, Ontario Institute for Cancer Research, Ovarian Cancer Canada and Terry Fox Research Institute that converge preclinical and clinical areas of interest.